AzTrials
AzTrials

Obstructive Sleep Apnea of ChildPhase 1/2NCT02247167

Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing.

A Phase 1/2 study testing adenotonsillectomy in people with Obstructive Sleep Apnea of Child, run by University of Roma La Sapienza at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sleep disordered breathing (SDB) is a common disease in both adults and children and is caused by the obstruction of the upper airway during sleep. Unlike adults, most cases of paediatric SDB are due to the presence of enlarged tonsils and adenoids, thus the main treatment option is adenotonsillectomy (AT). Read more about this study

Who is it for?
Ages 3 to 15 years
Conditions the study is for
Obstructive Sleep Apnea of Child
What is being tested?
adenotonsillectomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteItaly
Study dates
Feb 2012to Jul 2014
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children with diagnosed sleep breathing disorders

Who cannot join

  • epilepsy
  • acute or chronic cardiorespiratory or neuromuscular diseases
  • chronic inflammatory diseases
  • liver insufficiency
  • serious renal disorders
  • smoking
  • vitamin assumption

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Sapienza University of Rome, I Clinica Medica, Research Tower

    Rome, 00161

Other trials in Italy

About this study

Sleep disordered breathing (SDB) is a common disease in both adults and children and is caused by the obstruction of the upper airway during sleep. Unlike adults, most cases of paediatric SDB are due to the presence of enlarged tonsils and adenoids, thus the main treatment option is adenotonsillectomy (AT). It is well known that obstructive sleep apnoea (OSA) in adults increases the risk for hypertension, coronary artery disease and stroke, and there is now mounting evidence that SDB also has a significant impact on the cardiovascular system in children with reports of elevated blood pressure, endothelial dysfunction and altered autonomic cardiovascular control.

Oxidative stress seems to play a pivotal role in impairing flow-mediated dilation (FMD) and consequently enhancing cardiovascular risk in SDB patients but the underlying mechanism is still undefined.

Read more

Previously, we demonstrated that endothelial dysfunction is directly related to NADPH oxidase activation. Furthermore, recently we assessed the association between OSA, endothelial dysfunction and oxidative stress in adults showing that increased NADPH oxidase-generated oxidative stress and arterial dysfunction are partially reversed by nasal continuous positive airway pressure treatment.

There is evidence in literature that cardiovascular morbidities associated with SDB are potentially reversible in children; AT may have a significant role in reversing the cardiovascular sequelae of SDB (e.g. children with OSA).

Nowadays, there aren't studies that analyzed the role of NADPH oxidase-generated oxidative stress in SDB children.

The purpose of the current research project is to examine the role of NADPH oxidase activity, oxidative stress, inflammation and endothelial function in SDB children, understanding the mechanisms involved in this disease.

Furthermore we will analyse the effect of a AT on inflammation, oxidative stress, NADPH oxidase activity and endothelial function in SDB children.

Read the detailed description

Sleep disordered breathing (SDB) is a spectrum of diseases ranging from primary snoring to obstructive sleep apnoea (OSA). Recent studies suggested that the prevalence of SDB childhood was 7.4%. In patients with OSA, there are intermittent episodes of complete or partial obstruction leading to intermittent desaturations and/or arousals. This would result in either stimulation of sympathetic system or suppression of the vagal tone that may persist beyond sleep. The disturbance of the autonomic nervous system would result in significant changes in the cardiovascular system. The process of intermittent hypoxaemia and subsequent re-oxygenation also damages the endothelium because of the generation of free radicals. Furthermore, the excessive negative intra-thoracic pressure swing generated during the obstruction would also affect cardiac functions. In adults, OSA has been well documented to be associated with cardiovascular abnormalities such as hypertension, ischaemic heart disease, arrhythmia and heart failure.

Oxidative stress plays a crucial role in the initiation and progression of atherosclerosis. In particular, an imbalance between superoxide and nitric oxide production could be responsible for endothelial dysfunction, a key point for atherosclerotic process. Several oxidative stress-generating enzymes, including myeloperoxidase, xanthine oxidase and nicotinamide adenine dinucleotide phosphate (NADPH) may be implicated in arterial dysfunction; NADPH oxidase represents, in human, the most important source of cellular superoxide anion production. Experimental studies performed in animal models suggest a pivotal role of NADPH oxidase in modulating arterial tone. In particular, overexpression of gp91phox (NOX2), potentiates the hemodynamic response to angiotensin II. Furthermore, individuals with impaired dilation show an overexpression of the NADPH oxidase subunit p47phox in endothelial cells.

Previously, we demonstrated that endothelial dysfunction is directly related to NADPH oxidase activation; in particular we demonstrated that in patients with NADPH oxidase subunits deletion, as chronic granulomatous disease, the oxidative stress is lower and flow-mediate dilation is higher, compared to controls. Conversely, in other diseases characterized by high rate of cardiovascular events (OSAS, Peripheral arterial disease, metabolic syndrome, obesity and hypercholesterolemia), we found an endothelial dysfunction and a NOX2 overexpression.

Recently, we assessed the association between OSAS, endothelial dysfunction and oxidative stress in adults. Interestingly, the results of our study indicated that patients with OSAS have increased NOX2-generated oxidative stress and arterial dysfunction that are partially reversed by nasal continuous positive airway pressure (nCPAP) treatment.

There is evidence in literature that cardiovascular morbidities associated with SDB are potentially reversible in children; AT may have a significant role in reversing the cardiovascular sequelae of SDB (e.g. children affected by OSA).

The purpose of the current research project is to examine NADPH oxidase activity, oxidative stress, inflammation and endothelial function in children with SDB.

Expected outcomes and their interest in advances in the frontier of knowledge and their potential impact:

  1. understand the mechanisms mediated by inflammation and oxidative stress involved in SDB
  2. the assessment of NADPH oxidase activity could be a useful tool to identify SDB patients at high risk of cardiovascular events in order to prevent their dramatic complications.
  3. Analyse the effect of a surgical correction (e.g. adenotonsillectomy) on inflammation, oxidative stress, NADPH oxidase activity and endothelial function in children; adenotonsillectomy could represent a potential therapeutic option to reduce the high cardiovascular risk of SDB children.

The study will be divided in 2 phases: a cross-sectional and an interventional study.

  1. In the cross-sectional study we will include at least 100 children (50 SDB children with SDB and 50 controls), assessing markers of oxidative stress (serum isoprostanes), NADPH oxidase activity, inflammation, endothelial function (by flow-mediated dilation, FMD) and the carotid intima media thickness (IMT) measurement.
  2. In the interventional study we will include at least 10 with OSA and adenotonsillar hypertrophy that will undergo to adenotonsillectomy, evaluating markers of oxidative stress (serum isoprostanes), NADPH oxidase activity, inflammation and endothelial function before and after (at least 30 days) the surgical procedure.
Being tested
adenotonsillectomy
Keywords
obstructive sleep apnoea, oxidative stress, FMD
Medical subject headings
Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • adenotonsillectomyProcedure or surgery

    adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.

Study groups in NCT02247167
Study groupRoleWhat they receive
adenotonsillectomy (AT)ExperimentalChildren with SDB studied before and after before adenotonsillectomy.
Receives: Procedure: adenotonsillectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of flow mediated dilation (fmd)

    Measured: Baseline, week 4

Secondary outcomes (1)
  1. Assessment of isoprostanes 8 Iso-pgf2alpha (pg/ml) levels

    Measured: Baseline, 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2014 (estimated)
  2. Study startFeb 2012
  3. Primary completionMay 2014
  4. Study completionJul 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
Single blind
Who is masked
Investigator
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02247167
Sponsor's protocol ID
Sapienza-sdb
Other IDs
C26A13W4AK
Status last verified
Sep 2014
First submitted
9 Jul 2014
Last updated
23 Sep 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Del Ben M, Fabiani M, Loffredo L, Polimeni L, Carnevale R, Baratta F, Brunori M, Albanese F, Augelletti T, Violi F, Angelico F. Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulm Med. 2012 Jul 23;12:36. doi: 10.1186/1471-2466-12-36.

    PubMed 22824065
  • Loffredo L, Martino F, Carnevale R, Pignatelli P, Catasca E, Perri L, Calabrese CM, Palumbo MM, Baratta F, Del Ben M, Angelico F, Violi F. Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr. 2012 Dec;161(6):1004-9. doi: 10.1016/j.jpeds.2012.05.042. Epub 2012 Jun 23.

    PubMed 22727869
  • Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation. 2009 Oct 20;120(16):1616-22. doi: 10.1161/CIRCULATIONAHA.109.877191. Epub 2009 Oct 5.

    PubMed 19805647
  • Loffredo L, Zicari AM, Occasi F, Perri L, Carnevale R, Angelico F, Del Ben M, Martino F, Nocella C, Savastano V, Cesoni Marcelli A, Duse M, Violi F. Endothelial dysfunction and oxidative stress in children with sleep disordered breathing: role of NADPH oxidase. Atherosclerosis. 2015 May;240(1):222-7. doi: 10.1016/j.atherosclerosis.2015.03.024. Epub 2015 Mar 18.

    PubMed 25805361

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing adenotonsillectomy in people with Obstructive Sleep Apnea of Child, run by University of Roma La Sapienza at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of flow mediated dilation (fmd) (time frame: Baseline, week 4). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02247167, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2014.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in